Thursday, May 18, 2023 9:45:59 AM
https://stockcharts.com/h-sc/ui?s=ALIM
BRIEF-Alimera Acquires U.S. Commercial Rights To Yutiq®
REUTERS
7:05 AM ET May-18-2023
May 18 (Reuters) - Alimera Sciences Inc (ALIM.NaE):
* ALIMERA ACQUIRES U.S. COMMERCIAL RIGHTS TO YUTIQ®
* ALIMERA ACQUIRES U.S. COMMERCIAL RIGHTS TO YUTIQ® Source text for Eikon: Further company coverage:
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals. It operates through United States, internationally, and Operating Cost segments. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, clinics, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
Recent ALIM News
- Alimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate Update • GlobeNewswire Inc. • 04/30/2024 12:00:00 PM
- Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/20/2024 12:00:00 PM
- Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network • GlobeNewswire Inc. • 03/19/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/08/2024 10:23:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 01:32:14 PM
- Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results • GlobeNewswire Inc. • 03/07/2024 12:30:00 PM
- Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update • GlobeNewswire Inc. • 02/29/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:43:35 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:24:52 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 08:27:46 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/09/2024 10:25:06 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/09/2024 10:14:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 10:08:13 PM
- The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN® • GlobeNewswire Inc. • 02/08/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 05:49:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:02:52 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:02:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:01:17 PM
- Alimera Completes Recruitment for the Synchronicity Study • GlobeNewswire Inc. • 01/04/2024 01:00:00 PM
- Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/02/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/13/2023 10:20:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 10:09:52 PM
- Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 12/12/2023 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/28/2023 09:02:41 PM
FEATURED Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM